As of November 6, 2026, GRI Bio, Inc. is a publicly traded company (Nasdaq: GRI). No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G/A, May 13, 2026).
Is this your company?
About to sign with, pay or invest in GRI Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is GRI Bio, Inc. a real, registered company?
- GRI Bio, Inc. files with the SEC under CIK 1824293 (its SEC filings).
- Its shares are listed under the ticker GRI on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in La Jolla, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under GRI BIO, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Mitchell P. Kopin (filed 2026-05-13).
Who are GRI Bio, Inc.'s owners and officers?
GRI Bio, Inc.: incorporated in Delaware; business address in La Jolla, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-10-25)
- : Executive Officer (Form D, 2024-10-25)
- : Director (Form D, 2024-10-25)
- : Director (Form D, 2024-10-25)
- : Director (Form D, 2024-10-25)
- : Director (Form D, 2024-10-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Mitchell P. Kopin | 4.99% |
| Schedule 13G/A, 2026-05-13 | Mitchell P. Kopin | 5.9% |
| Schedule 13G/A, 2026-02-13 | Mitchell P. Kopin | 9.99% |
| Schedule 13G/A, 2026-02-10 | Lincoln Alternative Strategies LLC | 0% |
| Schedule 13G, 2025-12-29 | Lincoln Alternative Strategies LLC | 11.83% |
| Schedule 13G, 2025-12-17 | Mitchell P. Kopin | 9.99% |
Want the whole picture on GRI Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on GRI Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GRI Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has GRI Bio, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-10-25 | $762K | $762K |
| Form D, 2023-04-27 | $15.58M | $15.58M |
Latest IPO step: GRI Bio, Inc. filed its final IPO prospectus, ticker GRI (424B4, 2025-12-12).
IPO filings: 424B4, 2025-12-12, S-1/A, 2025-12-10, S-1, 2025-12-08, 424B4, 2025-04-02, S-1/A, 2025-03-26; ticker GRI on Nasdaq Capital Market.
Keep reading
More on GRI Bio, Inc. and the records around it.
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/gri-bio